Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
September 20, 2022 08:00 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has...
Applied Molecular Transport Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022 16:01 ET
|
Applied Molecular Transport Inc.
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Orphan indication with no FDA-approved productsCompany granted end of Phase 2 meeting with FDA to discuss...
Applied Molecular Transport Announces Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
July 06, 2022 08:00 ET
|
Applied Molecular Transport Inc.
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 –...
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
July 05, 2022 16:01 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its...
Applied Molecular Transport to Present at Upcoming June Investor Conferences
June 02, 2022 08:00 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in...
Applied Molecular Transport Provides Strategy Update
May 18, 2022 08:00 ET
|
Applied Molecular Transport Inc.
Company streamlines to prioritize resources on key proprietary clinical programs, including plans to advance AMT-101 into Phase 3 for chronic pouchitis Three Phase 2 top-line readouts for oral...
Applied Molecular Transport Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 09, 2022 16:01 ET
|
Applied Molecular Transport Inc.
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Independent Data Monitoring Committee (DMC) recommends advancing to Phase 3 Three Phase 2 top-line readouts...
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
May 05, 2022 16:01 ET
|
Applied Molecular Transport Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood,...
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
April 25, 2022 08:00 ET
|
Applied Molecular Transport Inc.
– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101 demonstrated favorable clinical activity and appeared safe and...
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
April 24, 2022 13:00 ET
|
Applied Molecular Transport Inc.
- Live Conference Call and Webcast on Monday, April 25, 2022, at 8:30 a.m. ET (5:30 a.m. PT) SOUTH SAN FRANCISCO, Calif., April 24, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc....